Please note that this product was withdrawn from the Community register of designated orphan medicinal products in February 2013 on request of the sponsor.
On 20 October 2004, orphan designation (EU/3/04/231) was granted by the European Commission to Neuraxo Biopharmaceuticals GmbH, Germany, for deferoxamine mesilate for the treatment of traumatic spinal-cord injury.
Neuraxo Biopharmaceuticals GmbH changed name to SCT Spinal Cord Therapeutics GmbH in May 2009.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
|Disease / condition||
Treatment of traumatic spinal cord injury
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;